Cargando…

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study

BACKGROUND: Hepatoma arterial-embolization prognostic (HAP) series scores have been proposed for prognostic prediction in patients with unresectable hepatocellular carcinoma (uHCC) undergoing transarterial chemoembolization (TACE). However, their prognostic value in TACE plus sorafenib (TACE-S) rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yejing, Wang, Enxin, Zhao, Shoujie, Han, Dandan, Zhao, Yan, Chen, Hui, Zhu, Jun, Han, Tenghui, Bai, Yang, Lou, Yanju, Zhang, Yongchao, Yang, Man, Zuo, Luo, Fan, Jiahao, Chen, Xing, Jia, Jia, Wu, Wenbin, Ren, Weirong, Bai, Tingting, Ma, Shouzheng, Xu, Fenghua, Tang, Yuxin, Han, Ying, Zhao, Junlong, Qi, Xingshun, Li, Jing, Du, Xilin, Chen, Dongfeng, Liu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911813/
https://www.ncbi.nlm.nih.gov/pubmed/36776366
http://dx.doi.org/10.3389/fonc.2022.983554
_version_ 1784885073376444416
author Zhu, Yejing
Wang, Enxin
Zhao, Shoujie
Han, Dandan
Zhao, Yan
Chen, Hui
Zhu, Jun
Han, Tenghui
Bai, Yang
Lou, Yanju
Zhang, Yongchao
Yang, Man
Zuo, Luo
Fan, Jiahao
Chen, Xing
Jia, Jia
Wu, Wenbin
Ren, Weirong
Bai, Tingting
Ma, Shouzheng
Xu, Fenghua
Tang, Yuxin
Han, Ying
Zhao, Junlong
Qi, Xingshun
Li, Jing
Du, Xilin
Chen, Dongfeng
Liu, Lei
author_facet Zhu, Yejing
Wang, Enxin
Zhao, Shoujie
Han, Dandan
Zhao, Yan
Chen, Hui
Zhu, Jun
Han, Tenghui
Bai, Yang
Lou, Yanju
Zhang, Yongchao
Yang, Man
Zuo, Luo
Fan, Jiahao
Chen, Xing
Jia, Jia
Wu, Wenbin
Ren, Weirong
Bai, Tingting
Ma, Shouzheng
Xu, Fenghua
Tang, Yuxin
Han, Ying
Zhao, Junlong
Qi, Xingshun
Li, Jing
Du, Xilin
Chen, Dongfeng
Liu, Lei
author_sort Zhu, Yejing
collection PubMed
description BACKGROUND: Hepatoma arterial-embolization prognostic (HAP) series scores have been proposed for prognostic prediction in patients with unresectable hepatocellular carcinoma (uHCC) undergoing transarterial chemoembolization (TACE). However, their prognostic value in TACE plus sorafenib (TACE-S) remains unknown. Here, we aim to evaluate their prognostic performance in such conditions and identify the best model for this combination therapy. METHODS: Between January 2012 and December 2018, consecutive patients with uHCC receiving TACE-S were recruited from 15 tertiary hospitals in China. Cox regression analyses were used to investigate the prognostic values of baseline factors and every scoring system. Their prognostic performance and discriminatory performance were evaluated and confirmed in subgroup analyses. RESULTS: A total of 404 patients were enrolled. In the whole cohort, the median follow-up period was 44.2 (interquartile range (IQR), 33.2–60.7) months, the median overall survival (OS) time was 13.2 months, and 336 (83.2%) patients died at the end of the follow-up period. According to multivariate analyses, HAP series scores were independent prognostic indicators of OS. In addition, the C-index, Akaike information criterion (AIC) values, and time-dependent area under the receiver operating characteristic (ROC) curve (AUC) indicated that modified HAP (mHAP)-III had the best predictive performance. Furthermore, the results remained consistent in most subsets of patients. CONCLUSION: HAP series scores exhibited good predictive ability in uHCC patients accepting TACE-S, and the mHAP-III score was found to be superior to the other HAP series scores in predicting OS. Future prospective high-quality studies should be conducted to confirm our results and help with treatment decision-making.
format Online
Article
Text
id pubmed-9911813
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99118132023-02-11 Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study Zhu, Yejing Wang, Enxin Zhao, Shoujie Han, Dandan Zhao, Yan Chen, Hui Zhu, Jun Han, Tenghui Bai, Yang Lou, Yanju Zhang, Yongchao Yang, Man Zuo, Luo Fan, Jiahao Chen, Xing Jia, Jia Wu, Wenbin Ren, Weirong Bai, Tingting Ma, Shouzheng Xu, Fenghua Tang, Yuxin Han, Ying Zhao, Junlong Qi, Xingshun Li, Jing Du, Xilin Chen, Dongfeng Liu, Lei Front Oncol Oncology BACKGROUND: Hepatoma arterial-embolization prognostic (HAP) series scores have been proposed for prognostic prediction in patients with unresectable hepatocellular carcinoma (uHCC) undergoing transarterial chemoembolization (TACE). However, their prognostic value in TACE plus sorafenib (TACE-S) remains unknown. Here, we aim to evaluate their prognostic performance in such conditions and identify the best model for this combination therapy. METHODS: Between January 2012 and December 2018, consecutive patients with uHCC receiving TACE-S were recruited from 15 tertiary hospitals in China. Cox regression analyses were used to investigate the prognostic values of baseline factors and every scoring system. Their prognostic performance and discriminatory performance were evaluated and confirmed in subgroup analyses. RESULTS: A total of 404 patients were enrolled. In the whole cohort, the median follow-up period was 44.2 (interquartile range (IQR), 33.2–60.7) months, the median overall survival (OS) time was 13.2 months, and 336 (83.2%) patients died at the end of the follow-up period. According to multivariate analyses, HAP series scores were independent prognostic indicators of OS. In addition, the C-index, Akaike information criterion (AIC) values, and time-dependent area under the receiver operating characteristic (ROC) curve (AUC) indicated that modified HAP (mHAP)-III had the best predictive performance. Furthermore, the results remained consistent in most subsets of patients. CONCLUSION: HAP series scores exhibited good predictive ability in uHCC patients accepting TACE-S, and the mHAP-III score was found to be superior to the other HAP series scores in predicting OS. Future prospective high-quality studies should be conducted to confirm our results and help with treatment decision-making. Frontiers Media S.A. 2023-01-27 /pmc/articles/PMC9911813/ /pubmed/36776366 http://dx.doi.org/10.3389/fonc.2022.983554 Text en Copyright © 2023 Zhu, Wang, Zhao, Han, Zhao, Chen, Zhu, Han, Bai, Lou, Zhang, Yang, Zuo, Fan, Chen, Jia, Wu, Ren, Bai, Ma, Xu, Tang, Han, Zhao, Qi, Li, Du, Chen and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhu, Yejing
Wang, Enxin
Zhao, Shoujie
Han, Dandan
Zhao, Yan
Chen, Hui
Zhu, Jun
Han, Tenghui
Bai, Yang
Lou, Yanju
Zhang, Yongchao
Yang, Man
Zuo, Luo
Fan, Jiahao
Chen, Xing
Jia, Jia
Wu, Wenbin
Ren, Weirong
Bai, Tingting
Ma, Shouzheng
Xu, Fenghua
Tang, Yuxin
Han, Ying
Zhao, Junlong
Qi, Xingshun
Li, Jing
Du, Xilin
Chen, Dongfeng
Liu, Lei
Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
title Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
title_full Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
title_fullStr Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
title_full_unstemmed Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
title_short Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
title_sort identify optimal hap series scores for unresectable hcc patients undergoing tace plus sorafenib: a chinese multicenter observational study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911813/
https://www.ncbi.nlm.nih.gov/pubmed/36776366
http://dx.doi.org/10.3389/fonc.2022.983554
work_keys_str_mv AT zhuyejing identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT wangenxin identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT zhaoshoujie identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT handandan identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT zhaoyan identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT chenhui identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT zhujun identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT hantenghui identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT baiyang identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT louyanju identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT zhangyongchao identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT yangman identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT zuoluo identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT fanjiahao identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT chenxing identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT jiajia identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT wuwenbin identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT renweirong identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT baitingting identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT mashouzheng identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT xufenghua identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT tangyuxin identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT hanying identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT zhaojunlong identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT qixingshun identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT lijing identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT duxilin identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT chendongfeng identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy
AT liulei identifyoptimalhapseriesscoresforunresectablehccpatientsundergoingtaceplussorafenibachinesemulticenterobservationalstudy